ABT-199-D10
Added to RFQ
For Research & Analytical Purposes. Not for Personal use.
Packaging & Handling
Indicative product packaging is shown for visual reference. Actual packaging may vary based on pack size, quantity, storage condition and shipping requirements.
Documentation Available
Detailed specifications, certificates, and supporting documents are available upon request.
Detailed specifications, certificates, and supporting documents are available upon request.
Storage: Refer MSDS for complete information.
Hazard: Refer MSDS for complete information.
ABT-199-D10 Product Information
ABT-199-D10 is listed under Stable Isotopes and is intended for analytical research, quality control and pharmaceutical reference standard applications. The product is supplied by Clearsynth under CAT No. CS-T-96398.
Clearsynth provides this compound for research and analytical use, with product information including CAS number, molecular formula, molecular weight and product enquiry details.
Technical Data
Product Name
ABT-199-D10
CAT No.
CS-T-96398
HSN Code
38229010
Country of Origin
Can be shipped from India, Canada and USA
Molecular Formula
C45H40D10ClN7O7S
Molecular Weight
878.5
Category
Storage Condition
Refer MSDS for complete information.
Hazard Compound
Refer MSDS for complete information.
Description
Regulatory Description
ABT-199-D10 is supplied with detailed characterization data compliant with regulatory guideline. ABT-199-D10 can be used for analytical method development, method validation (AMV), Quality Control (QC), ANDA-related analytical work, and commercial pharmaceutical research applications.
Overview
"ABT-199-D10 is a deuterized form of ABT 199 (A112430), which is a potent and selective BCL-2 inhibitor that achieves potent antitumor activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer."
Synonyms
ABT-199-D10
Application Notes
"ABT-199-D10 is a deuterized form of ABT 199 (A112430), which is a potent and selective BCL-2 inhibitor that achieves potent antitumor activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer."
Product Applications & Regulatory Search Terms
Useful product, supplier and regulatory search terms for this reference standard.